首页 > 最新文献

International Journal of Pharmaceutics最新文献

英文 中文
Comparative performance study of paperboard disposable spacers versus commercial valved holding chambers for aerosol delivery 用于气溶胶输送的纸板一次性间隔器与商用阀式保持室的性能比较研究。
IF 5.3 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-28 DOI: 10.1016/j.ijpharm.2024.124774

Purpose

The aim of this study is to evaluate and compare the performance, for the administration of fluticasone propionate with a pressurized metered-dose inhaler (pMDI), of two low-tech paperboard spacers versus two commercially available valved holding chambers (VHC).

Methods

According to the Canadian standard CAN/CSA-Z264.1–02, total emitted dose (TED) and aerodynamic size distribution were measured for the pMDI in combination with 4 different spacers: a homemade paper cup spacer, the DispozABLE® paperboard spacer, the AeroChamber Plus® plastic VHC, and the Vortex® aluminium VHC.

Results

The two disposable paperboard spacers had a lower TED compared to the aluminium VHC, but delivered more than 2.5 times the dose of fluticasone than the commercial plastic VHC. The 3 antistatic devices (i.e. the aluminium VHC, the paperboard DispozABLE® spacer and the paper cup spacer) delivered a significantly higher dose of fine particles than the less antistatic plastic VHC. Their fine particle fraction was statistically similar to that obtained with pMDI without spacer. This respirable fraction ensures an optimal therapeutic effect. All spacers limited the flow of coarse particles, thus avoiding adverse effects on the trachea and oropharynx.

Conclusion

We have shown that inexpensive and low-tech paperboard spacers are interesting alternatives for the administration of aerosols.
目的:本研究旨在评估和比较两种技术含量较低的纸板垫片与两种市售阀式容纳腔(VHC)在使用加压计量吸入器(pMDI)吸入丙酸氟替卡松时的性能:根据加拿大标准 CAN/CSA-Z264.1-02,测量了 pMDI 与 4 种不同隔板(自制纸杯隔板、DispozABLE® 纸板隔板、AeroChamber Plus® 塑料 VHC 和 Vortex® 铝制 VHC)组合使用时的总发射剂量(TED)和气动尺寸分布:结果:与铝制 VHC 相比,两种一次性纸板间隔器的 TED 较低,但氟替卡松的剂量却是商用塑料 VHC 的 2.5 倍以上。三种抗静电装置(即铝制 VHC、纸板 DispozABLE® 隔板和纸杯隔板)的细颗粒剂量明显高于抗静电性较低的塑料 VHC。从统计学角度来看,它们的细颗粒分量与使用不带间隔器的 pMDI 得到的细颗粒分量相似。这种可吸入部分确保了最佳治疗效果。所有间隔器都限制了粗颗粒的流动,从而避免了对气管和口咽的不良影响:我们的研究表明,价格低廉、技术含量不高的纸板垫片是施用气溶胶的有趣替代品。
{"title":"Comparative performance study of paperboard disposable spacers versus commercial valved holding chambers for aerosol delivery","authors":"","doi":"10.1016/j.ijpharm.2024.124774","DOIUrl":"10.1016/j.ijpharm.2024.124774","url":null,"abstract":"<div><h3>Purpose</h3><div>The aim of this study is to evaluate and compare the performance, for the administration of fluticasone propionate with a pressurized metered-dose inhaler (pMDI), of two low-tech paperboard spacers versus two commercially available valved holding chambers (VHC).</div></div><div><h3>Methods</h3><div>According to the Canadian standard CAN/CSA-Z264.1–02, total emitted dose (TED) and aerodynamic size distribution were measured for the pMDI in combination with 4 different spacers: a homemade paper cup spacer, the DispozABLE® paperboard spacer, the AeroChamber Plus® plastic VHC, and the Vortex® aluminium VHC.</div></div><div><h3>Results</h3><div>The two disposable paperboard spacers had a lower TED compared to the aluminium VHC, but delivered more than 2.5 times the dose of fluticasone than the commercial plastic VHC. The 3 antistatic devices (<em>i.e.</em> the aluminium VHC, the paperboard DispozABLE® spacer and the paper cup spacer) delivered a significantly higher dose of fine particles than the less antistatic plastic VHC. Their fine particle fraction was statistically similar to that obtained with pMDI without spacer. This respirable fraction ensures an optimal therapeutic effect. All spacers limited the flow of coarse particles, thus avoiding adverse effects on the trachea and oropharynx.</div></div><div><h3>Conclusion</h3><div>We have shown that inexpensive and low-tech paperboard spacers are interesting alternatives for the administration of aerosols<em>.</em></div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142346628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Panax notoginseng saponins and acetylsalicylic acid co-delivered liposomes for targeted treatment of ischemic stroke. 三七皂苷和乙酰水杨酸共给药脂质体用于缺血性中风的靶向治疗。
IF 5.3 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-28 DOI: 10.1016/j.ijpharm.2024.124782
Hao Cui, Yanchi Liu, Ying Yu, Dong Lv, Sha Ma, Mingju Gao, Ye Yang, Cheng Yuan, Yuan Liu, Chengxiao Wang

In this study, we aimed to develop brain-targeted co-delivery liposomes for the concurrent delivery of Panax notoginseng saponins (PNS) and acetylsalicylic acid (ASA) for the treatment of ischemic stroke. Within this system, PNS served as a cholesterol substitute, integrating into the phospholipid bilayer of the liposomes, while ASA was encapsulated internally. A poly-2-methacryloyloxyethyl phosphorylcholine (PMPC) polymer was synthesized and incorporated into the liposome surface. This formulation demonstrated an enhanced PNS-loading capacity and facilitated the synchronized delivery of key saponin components. Following PMPC modification, the liposomes exhibited prolonged circulation and improved transport across the blood-brain barrier (BBB) through acetylcholine receptor-mediated pathways. Furthermore, the co-delivery system exhibited enhanced therapeutic efficacy in a rat model of cerebral ischemia-reperfusion injury via the phosphoinositide 3-kinase/protein kinase C pathway. Additional analyses revealed significant effects on the metabolism of neurotransmitters, amino acids, folate, and various other pathways, indicating a multi-faceted therapeutic effect. Overall, this study presents an innovative research strategy for the comprehensive delivery of diverse components in traditional Chinese medicine formulations, highlighting the potential for synergistic treatments that combine traditional Chinese medicine with chemical agents.

本研究旨在开发脑靶向协同给药脂质体,用于同时给药三七皂苷(PNS)和乙酰水杨酸(ASA),以治疗缺血性中风。在这一系统中,三七皂苷作为胆固醇替代物融入脂质体的磷脂双分子层,而ASA则被包裹在脂质体内部。我们合成了一种聚 2-甲基丙烯酰氧乙基磷酰胆碱(PMPC)聚合物,并将其融入脂质体表面。这种配方显示出更强的 PNS 负荷能力,并促进了关键皂苷成分的同步递送。经 PMPC 改性后,脂质体的循环时间延长,并通过乙酰胆碱受体介导的途径改善了通过血脑屏障(BBB)的转运。此外,在大鼠脑缺血再灌注损伤模型中,联合给药系统通过磷酸肌酸 3- 激酶/蛋白激酶 C 途径提高了疗效。其他分析表明,该药物对神经递质、氨基酸、叶酸和其他各种途径的代谢均有明显影响,显示出多方面的治疗效果。总之,本研究提出了一种创新的研究策略,用于在传统中药配方中全面传递各种成分,突出了传统中药与化学制剂相结合的协同治疗潜力。
{"title":"Panax notoginseng saponins and acetylsalicylic acid co-delivered liposomes for targeted treatment of ischemic stroke.","authors":"Hao Cui, Yanchi Liu, Ying Yu, Dong Lv, Sha Ma, Mingju Gao, Ye Yang, Cheng Yuan, Yuan Liu, Chengxiao Wang","doi":"10.1016/j.ijpharm.2024.124782","DOIUrl":"https://doi.org/10.1016/j.ijpharm.2024.124782","url":null,"abstract":"<p><p>In this study, we aimed to develop brain-targeted co-delivery liposomes for the concurrent delivery of Panax notoginseng saponins (PNS) and acetylsalicylic acid (ASA) for the treatment of ischemic stroke. Within this system, PNS served as a cholesterol substitute, integrating into the phospholipid bilayer of the liposomes, while ASA was encapsulated internally. A poly-2-methacryloyloxyethyl phosphorylcholine (PMPC) polymer was synthesized and incorporated into the liposome surface. This formulation demonstrated an enhanced PNS-loading capacity and facilitated the synchronized delivery of key saponin components. Following PMPC modification, the liposomes exhibited prolonged circulation and improved transport across the blood-brain barrier (BBB) through acetylcholine receptor-mediated pathways. Furthermore, the co-delivery system exhibited enhanced therapeutic efficacy in a rat model of cerebral ischemia-reperfusion injury via the phosphoinositide 3-kinase/protein kinase C pathway. Additional analyses revealed significant effects on the metabolism of neurotransmitters, amino acids, folate, and various other pathways, indicating a multi-faceted therapeutic effect. Overall, this study presents an innovative research strategy for the comprehensive delivery of diverse components in traditional Chinese medicine formulations, highlighting the potential for synergistic treatments that combine traditional Chinese medicine with chemical agents.</p>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142346641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A novel temperature-controlled media milling device to produce drug nanocrystals at the laboratory scale 用于在实验室规模生产药物纳米晶体的新型温控介质研磨装置。
IF 5.3 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-28 DOI: 10.1016/j.ijpharm.2024.124780
Poor aqueous solubility of preexisting and emerging drug molecules is a common issue faced in the field of pharmaceutics. To address this, particle size reduction techniques, including drug micro- and nanonisation have been widely employed. Nanocrystals (NCs), drug particles with particle sizes below 1 µm, offer high drug content, improved dissolution, and long-acting capabilities. Media milling is the most used method to prepare NCs using of-the-shelf machinery, both at the laboratory and industrial scales. However, early NCs development, especially when limited amounts of the active are available, require the use of milligram-scale media milling. This study introduces a novel mini-scale milling device (Mini-mill) that incorporates temperature control through a water-cooled jacket. The device was used to produce NCs of three model hydrophobic drugs, itraconazole, ivermectin and curcumin, with lowest particle sizes of 162.5 ± 0.4 nm, 178 ± 2 nm, and 116.7 ± 0.7 nm, respectively. Precise control of milling temperature was achieved at 15, 45, and 75°C, with drug dependent particle size reduction trends, with no adverse effects on the milling materials or polymorphic changes in the NCs, as confirmed by calorimetric analysis. Finally, a scale-up feasibility study was carried out in a lab-scale NanoDisp®, confirming that the novel Mini-mills are a material-efficient tool for early formulation development, with potential for scale-up to commercial mills.
现有和新出现的药物分子水溶性差是制药领域面临的一个共同问题。为解决这一问题,包括药物微纳米化在内的粒径缩小技术已被广泛采用。纳米晶体(NC)是粒径小于 1 微米的药物颗粒,具有药物含量高、溶解性好和长效等特点。介质研磨是使用现成机器制备 NCs 的最常用方法,无论是在实验室还是在工业规模上都是如此。然而,NCs 的早期开发,尤其是在活性物质数量有限的情况下,需要使用毫克级介质研磨。本研究介绍了一种新型微型研磨设备(Mini-mill),该设备通过水冷夹套进行温度控制。该装置用于生产三种疏水性药物(伊曲康唑、伊维菌素和姜黄素)的 NCs,最低粒径分别为 162.5 ± 0.4 nm、178 ± 2 nm 和 116.7 ± 0.7 nm。制粉温度精确控制在 15、45 和 75°C,粒度减小趋势与药物有关,对制粉材料没有不利影响,NC 也没有发生多晶型变化,这一点已得到量热分析的证实。最后,在实验室规模的 NanoDisp® 中进行了放大可行性研究,证实新型迷你研磨机是一种用于早期制剂开发的材料高效工具,具有放大到商用研磨机的潜力。
{"title":"A novel temperature-controlled media milling device to produce drug nanocrystals at the laboratory scale","authors":"","doi":"10.1016/j.ijpharm.2024.124780","DOIUrl":"10.1016/j.ijpharm.2024.124780","url":null,"abstract":"<div><div>Poor aqueous solubility of preexisting and emerging drug molecules is a common issue faced in the field of pharmaceutics. To address this, particle size reduction techniques, including drug micro- and nanonisation have been widely employed. Nanocrystals (NCs), drug particles with particle sizes below 1 µm, offer high drug content, improved dissolution, and long-acting capabilities. Media milling is the most used method to prepare NCs using of-the-shelf machinery, both at the laboratory and industrial scales. However, early NCs development, especially when limited amounts of the active are available, require the use of milligram-scale media milling. This study introduces a novel mini-scale milling device (Mini-mill) that incorporates temperature control through a water-cooled jacket. The device was used to produce NCs of three model hydrophobic drugs, itraconazole, ivermectin and curcumin, with lowest particle sizes of 162.5 ± 0.4 nm, 178 ± 2 nm, and 116.7 ± 0.7 nm, respectively. Precise control of milling temperature was achieved at 15, 45, and 75°C, with drug dependent particle size reduction trends, with no adverse effects on the milling materials or polymorphic changes in the NCs, as confirmed by calorimetric analysis. Finally, a scale-up feasibility study was carried out in a lab-scale NanoDisp®, confirming that the novel Mini-mills are a material-efficient tool for early formulation development, with potential for scale-up to commercial mills.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142346624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Application of shadowgraph imaging (SGI) particle characterisation data to interpret the impact of varying test conditions on powder dissolution and to develop an automated agglomeration identification method (AIM) in the USP flow-through apparatus 应用阴影图成像 (SGI) 颗粒表征数据来解释不同测试条件对动力溶解的影响,并在美国药典 (USP) 直通仪器中开发自动结块识别方法 (AIM)。
IF 5.3 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-28 DOI: 10.1016/j.ijpharm.2024.124778
The aims of this work were 1) to explore the application of shadowgraph imaging (SGI) as a real time monitoring tool to characterize ibuprofen particle behaviour during dissolution testing under various conditions in the USP 4 flow-through apparatus and 2) to investigate the potential to develop an SGI-based automated agglomeration identification method (AIM) for real time agglomerate detection during dissolution testing. The effect of surfactant addition, changes in the drug mass and flow rate, the use of sieved and un-sieved powder fractions, and the use of different drug crystal habits were investigated. Videos at every sampling time point during dissolution were taken and analysed by SGI. The AIM was developed to characterize agglomerates based on two criteria – size and solidity. All detections were confirmed by manual video observation and a reference agglomerate data set. The method was validated under new dissolution conditions with un-sieved particles. Characterisation of particle dispersion behaviour by SGI enabled interpretation of the impact of dissolution test conditions. Higher numbers of early detections reflected greater dissolution rates with increased surfactant concentration, using sieved fraction or plate-shaped crystals, but was impacted by drug mass tested. An AIM was successfully developed and applied to detect agglomerates during dissolution, suggesting potential, with appropriate method development, for application in quality control.
这项工作的目的是:1)探索阴影图成像 (SGI) 作为实时监测工具的应用,以表征布洛芬颗粒在 USP 4 流通设备中各种条件下进行溶解测试期间的表现;2)研究开发基于 SGI 的自动结块识别方法 (AIM) 的潜力,以便在溶解测试期间进行实时结块检测。研究了添加表面活性剂、改变药物质量和流速、使用过筛和未过筛粉末馏分以及使用不同药物晶体习性的影响。SGI 拍摄并分析了溶解过程中每个取样时间点的视频。AIM 的开发是为了根据两个标准--大小和坚固程度--来表征团块。所有检测结果均通过人工视频观察和参考结块数据集进行确认。在新的溶解条件下,使用未松散颗粒对该方法进行了验证。通过 SGI 对颗粒分散行为的表征,可以解释溶解试验条件的影响。使用筛分颗粒或板状晶体,早期检测到的颗粒数量越多,表明表面活性剂浓度越高,溶出率越高,但受测试药物质量的影响也越大。成功开发并应用 AIM 来检测溶解过程中的结块,这表明在适当的方法开发下,AIM 有可能应用于质量控制。
{"title":"Application of shadowgraph imaging (SGI) particle characterisation data to interpret the impact of varying test conditions on powder dissolution and to develop an automated agglomeration identification method (AIM) in the USP flow-through apparatus","authors":"","doi":"10.1016/j.ijpharm.2024.124778","DOIUrl":"10.1016/j.ijpharm.2024.124778","url":null,"abstract":"<div><div>The aims of this work were 1) to explore the application of shadowgraph imaging (SGI) as a real time monitoring tool to characterize ibuprofen particle behaviour during dissolution testing under various conditions in the USP 4 flow-through apparatus and 2) to investigate the potential to develop an SGI-based automated agglomeration identification method (AIM) for real time agglomerate detection during dissolution testing. The effect of surfactant addition, changes in the drug mass and flow rate, the use of sieved and un-sieved powder fractions, and the use of different drug crystal habits were investigated. Videos at every sampling time point during dissolution were taken and analysed by SGI. The AIM was developed to characterize agglomerates based on two criteria – size and solidity. All detections were confirmed by manual video observation and a reference agglomerate data set. The method was validated under new dissolution conditions with un-sieved particles. Characterisation of particle dispersion behaviour by SGI enabled interpretation of the impact of dissolution test conditions. Higher numbers of early detections reflected greater dissolution rates with increased surfactant concentration, using sieved fraction or plate-shaped crystals, but was impacted by drug mass tested. An AIM was successfully developed and applied to detect agglomerates during dissolution, suggesting potential, with appropriate method development, for application in quality control.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142346626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent trends on polycaprolactone as sustainable polymer-based drug delivery system in the treatment of cancer: Biomedical applications and nanomedicine 聚己内酯作为基于聚合物的可持续给药系统治疗癌症的最新趋势:生物医学应用和纳米医学。
IF 5.3 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-27 DOI: 10.1016/j.ijpharm.2024.124734
The unique properties—such as biocompatibility, biodegradability, bio-absorbability, low cost, easy fabrication, and high versatility—have made polycaprolactone (PCL) the center of attraction for researchers. The derived introduction in this manuscript gives a pretty detailed overview of PCL, so you can first brush up on it. Discussion on the various PCL-based derivatives involves, but is not limited to, poly(ε-caprolactone-co-lactide) (PCL-co-LA), PCL-g-PEG, PCL-g-PMMA, PCL-g-chitosan, PCL-b-PEO, and PCL-g-PU specific properties and their probable applications in biomedicine. This paper has considered examining the differences in the diverse disease subtypes and the therapeutic value of using PCL. Advanced strategies for PCL in delivery systems are also considered. In addition, this review discusses recently patented products to provide a snapshot of recent updates in this field. Furthermore, the text probes into recent advances in PCL-based DDS, for example, nanoparticles, liposomes, hydrogels, and microparticles, while giving special attention to comparing the esters in the delivery of bioactive compounds such as anticancer drugs. Finally, we review future perspectives on using PCL in biomedical applications and the hurdles of PCL-based drug delivery, including fine-tuning mechanical strength/degradation rate, biocompatibility, and long-term effects in living systems.
聚己内酯(PCL)具有生物相容性、生物可降解性、生物可吸收性、低成本、易制造和高通用性等独特性能,因此成为研究人员关注的焦点。本手稿的引言对 PCL 做了相当详细的概述,您可以先了解一下。关于以 PCL 为基础的各种衍生物的讨论涉及但不限于聚(ε-己内酯-共内酯) (PCL-co-LA)、PCL-g-PEG、PCL-g-PMMA、PCL-g-壳聚糖、PCL-b-PEO 和 PCL-g-PU 的具体特性及其在生物医学中的可能应用。本文探讨了不同疾病亚型的差异以及使用 PCL 的治疗价值。此外,还考虑了 PCL 在传输系统中的先进策略。此外,本综述还讨论了最近获得专利的产品,为该领域的最新进展提供了一个缩影。此外,文中还探讨了基于 PCL 的 DDS(例如纳米颗粒、脂质体、水凝胶和微颗粒)的最新进展,同时特别关注了酯类在输送生物活性化合物(例如抗癌药物)方面的比较。最后,我们回顾了在生物医学应用中使用 PCL 的未来前景以及基于 PCL 的药物递送所面临的障碍,包括微调机械强度/降解率、生物相容性以及在生命系统中的长期效应。
{"title":"Recent trends on polycaprolactone as sustainable polymer-based drug delivery system in the treatment of cancer: Biomedical applications and nanomedicine","authors":"","doi":"10.1016/j.ijpharm.2024.124734","DOIUrl":"10.1016/j.ijpharm.2024.124734","url":null,"abstract":"<div><div>The unique properties—such as biocompatibility, biodegradability, bio-absorbability, low cost, easy fabrication, and high versatility—have made polycaprolactone (PCL) the center of attraction for researchers. The derived introduction in this manuscript gives a pretty detailed overview of PCL, so you can first brush up on it. Discussion on the various PCL-based derivatives involves, but is not limited to, poly(ε-caprolactone-co-lactide) (PCL-co-LA), PCL-g-PEG, PCL-g-PMMA, PCL-g-chitosan, PCL-b-PEO, and PCL-g-PU specific properties and their probable applications in biomedicine. This paper has considered examining the differences in the diverse disease subtypes and the therapeutic value of using PCL. Advanced strategies for PCL in delivery systems are also considered. In addition, this review discusses recently patented products to provide a snapshot of recent updates in this field. Furthermore, the text probes into recent advances in PCL-based DDS, for example, nanoparticles, liposomes, hydrogels, and microparticles, while giving special attention to comparing the esters in the delivery of bioactive compounds such as anticancer drugs. Finally, we review future perspectives on using PCL in biomedical applications and the hurdles of PCL-based drug delivery, including fine-tuning mechanical strength/degradation rate, biocompatibility, and long-term effects in living systems.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142346643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bioinspired wound dressing: Investigating coelomic fluid-enhanced chitosan/polyvinyl alcohol nanofibers 生物启发的伤口敷料:研究肠液增强壳聚糖/聚乙烯醇纳米纤维。
IF 5.3 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-27 DOI: 10.1016/j.ijpharm.2024.124765
The electrospun mats consisting of integrated coelomic fluid (CF) and chitosan (Chs) into polyvinyl alcohol (PVA) nanofibers were produced and evaluated for use as wound dressings. CF was obtained from earthworms (Eisenia andrei (Fetida)) using an electric shock method, while Chs was chemically produced from shrimp chitin and then characterized using titration, Fourier transform infrared (FT-IR) spectroscopy, and viscometry. The wound dressings with different CF contents were evaluated for their antibacterial, antioxidant, and cell viability properties. The dressings infused with CF showed significantly higher antibacterial and antioxidant activity, as well as improved cell viability compared to the control without CF. In vivo studies using adult Wistar albino rats showed that the Chs/PVA/CF wound dressings promoted wound healing and re-epithelialization. Moreover, histological examinations of the injuries coated with Chs/PVA/CF displayed improved re-epithelialization. These results suggest that the Chs/PVA/CF nanofiber has the potential for use as a wound dressing material.
研究人员制备了将肠液(CF)和壳聚糖(Chs)融入聚乙烯醇(PVA)纳米纤维的电纺垫,并对其作为伤口敷料的用途进行了评估。CF 是用电击法从蚯蚓(Eisenia andrei (Fetida))中获得的,而 Chs 是用化学方法从虾甲壳素中获得的,然后用滴定法、傅立叶变换红外光谱法和粘度计对其进行表征。对不同 CF 含量的伤口敷料进行了抗菌、抗氧化和细胞活力特性评估。与不含 CF 的对照组相比,注入 CF 的敷料显示出更高的抗菌和抗氧化活性,细胞存活率也有所提高。使用成年 Wistar 白化大鼠进行的体内研究表明,Chs/PVA/CF 伤口敷料可促进伤口愈合和再上皮化。此外,对涂有 Chs/PVA/CF 的伤口进行的组织学检查显示,伤口的再上皮化得到了改善。这些结果表明,Chs/PVA/CF 纳米纤维具有用作伤口敷料材料的潜力。
{"title":"Bioinspired wound dressing: Investigating coelomic fluid-enhanced chitosan/polyvinyl alcohol nanofibers","authors":"","doi":"10.1016/j.ijpharm.2024.124765","DOIUrl":"10.1016/j.ijpharm.2024.124765","url":null,"abstract":"<div><div>The electrospun mats consisting of integrated coelomic fluid (CF) and chitosan (Chs) into polyvinyl alcohol (PVA) nanofibers were produced and evaluated for use as wound dressings. CF was obtained from earthworms (<em>Eisenia andrei (Fetida)</em>) using an electric shock method, while Chs was chemically produced from shrimp chitin and then characterized using titration, Fourier transform infrared (FT-IR) spectroscopy, and viscometry. The wound dressings with different CF contents were evaluated for their antibacterial, antioxidant, and cell viability properties. The dressings infused with CF showed significantly higher antibacterial and antioxidant activity, as well as improved cell viability compared to the control without CF. <em>In vivo</em> studies using adult Wistar albino rats showed that the Chs/PVA/CF wound dressings promoted wound healing and re-epithelialization. Moreover, histological examinations of the injuries coated with Chs/PVA/CF displayed improved re-epithelialization. These results suggest that the Chs/PVA/CF nanofiber has the potential for use as a wound dressing material.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142346627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Microbubble-laden aerosols improve post-nasal aerosol penetration efficiency in a preterm neonate model 在早产新生儿模型中,微气泡气溶胶提高了鼻后气溶胶渗透效率。
IF 5.3 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-27 DOI: 10.1016/j.ijpharm.2024.124772
Nebulized lung surfactant therapy has been a neonatology long-pursued goal. Nevertheless, many clinical trials have yet to show a clear clinical efficacy of nebulized surfactant, which, in part, is due to the technical challenges of delivering aerosols to the lungs of preterm neonates. The study aimed to test microbubbles for improving lung deposition in preterm neonates. An in vitro testing method was developed to replicate the clinical environment; it used a 3D-printed preterm neonate model, connected to a high-flow nasal cannula (HFNC) and a vibrating mesh nebulizer. The flow rate of the HFNC mirrored that used in the clinics (i.e., 4, 6, and 8 L/min). Followingly, the lung penetrations of aerosols with and without microbubbles were compared. The aerodynamic diameter of aerosols with microbubbles (MMAD=1.75 μm) was lower than that of the counterpart (MMAD=2.25 μm). Microbubble-laden aerosols had a significantly higher number of microbubbles that were below 1.0 μm. Microbubble-laden aerosols had dramatically higher lung penetration in the preterm model; lung penetration efficiencies were 30.0, 25.5, and 17.5 % at 4, 6, and 8 L/min, respectively, whereas the lung penetration efficiency for conventionally nebulized aerosols was below 1.25 % in the three flow rates.
雾化肺表面活性物质疗法是新生儿科长期追求的目标。然而,许多临床试验尚未显示出雾化表面活性物质的明确临床疗效,部分原因是向早产新生儿肺部输送气溶胶的技术挑战。该研究旨在测试微气泡对早产新生儿肺部沉积的改善作用。研究人员开发了一种体外测试方法来复制临床环境;该方法使用了一个三维打印的早产新生儿模型,该模型与一个高流量鼻插管(HFNC)和一个振动网状雾化器相连。HFNC 的流速与临床使用的流速一致(即 4、6 和 8 升/分钟)。随后,比较了有微气泡和无微气泡气溶胶的肺穿透率。含有微气泡的气溶胶的气动直径(MMAD=1.75 μm)低于不含微气泡的气溶胶(MMAD=2.25 μm)。含有微气泡的气溶胶中低于 1.0 微米的微气泡数量明显较多。在早产儿模型中,微气泡气溶胶的肺穿透率明显更高;在 4、6 和 8 升/分钟时,肺穿透率分别为 30.0%、25.5% 和 17.5%,而在这三种流速下,传统雾化气溶胶的肺穿透率均低于 1.25%。
{"title":"Microbubble-laden aerosols improve post-nasal aerosol penetration efficiency in a preterm neonate model","authors":"","doi":"10.1016/j.ijpharm.2024.124772","DOIUrl":"10.1016/j.ijpharm.2024.124772","url":null,"abstract":"<div><div>Nebulized lung surfactant therapy has been a neonatology long-pursued goal. Nevertheless, many clinical trials have yet to show a clear clinical efficacy of nebulized surfactant, which, in part, is due to the technical challenges of delivering aerosols to the lungs of preterm neonates. The study aimed to test microbubbles for improving lung deposition in preterm neonates. An in vitro testing method was developed to replicate the clinical environment; it used a 3D-printed preterm neonate model, connected to a high-flow nasal cannula (HFNC) and a vibrating mesh nebulizer. The flow rate of the HFNC mirrored that used in the clinics (i.e., 4, 6, and 8 L/min). Followingly, the lung penetrations of aerosols with and without microbubbles were compared. The aerodynamic diameter of aerosols with microbubbles (MMAD=1.75 μm) was lower than that of the counterpart (MMAD=2.25 μm). Microbubble-laden aerosols had a significantly higher number of microbubbles that were below 1.0 μm. Microbubble-laden aerosols had dramatically higher lung penetration in the preterm model; lung penetration efficiencies were 30.0, 25.5, and 17.5 % at 4, 6, and 8 L/min, respectively, whereas the lung penetration efficiency for conventionally nebulized aerosols was below 1.25 % in the three flow rates.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142346638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Particulate atomisation design methods for the development and engineering of advanced drug delivery systems: A review 用于开发和设计先进给药系统的微粒雾化设计方法:综述。
IF 5.3 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-27 DOI: 10.1016/j.ijpharm.2024.124771
The role and opportunities presented by particulate technologies (due to novel processing methods and advanced materials) have multiplied over the last few decades, leading to promising and ideal properties for drug delivery. For example, the dissolution and bioavailability of poorly soluble drug substances and achieving site- specific drug delivery with a desired release profile are crucial aspects of forming (to some extent) state-of-the-art platforms. Atomisation techniques are intended to achieve efficient control over particle size, improved processing time, improved drug loading efficiency, and the opportunity to encapsulate a broad range of viable yet sensitive therapeutic moieties. Particulate engineering through atomization is accomplished by employing various mechanisms such as air, no air, centrifugal, electrohydrodynamic, acoustic, and supercritical fluid driven processes. These driving forces overcome capillary stresses (e.g., liquid viscosity, surface tension) and transform formulation media (liquid) into fine droplets. More frequently, solvent removal, multiple methods are included to reduce the final size distribution. Nevertheless, a thorough understanding of fluid mechanics, thermodynamics, heat, and mass transfer is imperative to appreciate and predict outputs in real time. More so, in recent years, several advancements have been introduced to improve such processes through complex particle design coupled with quality by-design (QbD) yielding optimal particulate geometry in a predictable manner. Despite these valuable and numerous advancements, atomisation techniques face difficulty scaling up from laboratory scales to manufacturing industry scales. This review details the various atomisation techniques (from design to mechanism) along with examples of drug delivery systems developed. In addition, future perspectives and bottlenecks are provided while highlighting current and selected seminal developments in the field.
过去几十年来,微粒技术(由于新型加工方法和先进材料)所发挥的作用和带来的机遇成倍增加,为给药带来了前景广阔的理想特性。例如,溶解性差的药物物质的溶解性和生物利用度,以及实现特定部位给药和理想的释放曲线,都是形成(在一定程度上)最先进平台的关键方面。雾化技术旨在实现对粒度的有效控制,缩短加工时间,提高药物负载效率,并有机会封装各种可行但敏感的治疗分子。雾化微粒工程是通过采用各种机制(如空气、无空气、离心、电流体动力、声波和超临界流体驱动过程)来实现的。这些驱动力可克服毛细管应力(如液体粘度、表面张力),将配方介质(液体)转化为细小液滴。更常见的方法是去除溶剂,采用多种方法来减少最终的粒度分布。然而,要了解并实时预测输出结果,就必须对流体力学、热力学、传热和传质有透彻的了解。此外,近年来,通过复杂的颗粒设计和质量设计(QbD),以可预测的方式获得最佳颗粒几何形状,从而改进了此类工艺。尽管取得了这些宝贵的进步,但雾化技术仍难以从实验室规模扩展到制造业规模。本综述详细介绍了各种雾化技术(从设计到机制)以及所开发的给药系统实例。此外,还提供了未来展望和瓶颈问题,同时重点介绍了该领域当前和选定的开创性发展。
{"title":"Particulate atomisation design methods for the development and engineering of advanced drug delivery systems: A review","authors":"","doi":"10.1016/j.ijpharm.2024.124771","DOIUrl":"10.1016/j.ijpharm.2024.124771","url":null,"abstract":"<div><div>The role and opportunities presented by particulate technologies (due to novel processing methods and advanced materials) have multiplied over the last few decades, leading to promising and ideal properties for drug delivery. For example, the dissolution and bioavailability of poorly soluble drug substances and achieving site- specific drug delivery with a desired release profile are crucial aspects of forming (to some extent) state-of-the-art platforms. Atomisation techniques are intended to achieve efficient control over particle size, improved processing time, improved drug loading efficiency, and the opportunity to encapsulate a broad range of viable yet sensitive therapeutic moieties. Particulate engineering through atomization is accomplished by employing various mechanisms such as air, no air, centrifugal, electrohydrodynamic, acoustic, and supercritical fluid driven processes. These driving forces overcome capillary stresses (e.g., liquid viscosity, surface tension) and transform formulation media (liquid) into fine droplets. More frequently, solvent removal, multiple methods are included to reduce the final size distribution. Nevertheless, a thorough understanding of fluid mechanics, thermodynamics, heat, and mass transfer is imperative to appreciate and predict outputs in real time. More so, in recent years, several advancements have been introduced to improve such processes through complex particle design coupled with quality by-design (QbD) yielding optimal particulate geometry in a predictable manner. Despite these valuable and numerous advancements, atomisation techniques face difficulty scaling up from laboratory scales to manufacturing industry scales. This review details the various atomisation techniques (from design to mechanism) along with examples of drug delivery systems developed. In addition, future perspectives and bottlenecks are provided while highlighting current and selected seminal developments in the field.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142346656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimization of chitosan-gelatin-based 3D-printed scaffolds for tissue engineering and drug delivery applications 基于壳聚糖-明胶的三维打印支架在组织工程和药物输送应用中的优化。
IF 5.3 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-27 DOI: 10.1016/j.ijpharm.2024.124776
The combination of biocompatible materials and advanced three-dimensional (3D) additive manufacturing technologies holds great potential in the development of finely tuned complex scaffolds with reproducible macro- and micro-structural characteristics for biomedical applications, such as tissue engineering and drug delivery. In this study, biocompatible printable inks based on chitosan, collagen and gelatin were developed and 3D-printed with a pneumatic-based extrusion printer. The printability of various chitosan–gelatin (CS-Gel) hydrogel inks was assessed by evaluating the quality of the printed constructs. The inks required an extrusion pressure of 150 ± 40 MPa with G22 and G25 nozzles for optimal printing. Inks with low chitosan concentrations (<4% w/v) exhibited poor printability, while inks with 4 % w/v chitosan and 1 % w/v gelatin (CG) demonstrated satisfactory extrusion and printing quality. The addition of collagen (0.1 % w/v) to the optimized ink (CGC) did not compromise printability. Post-printing stabilization using KOH produced self-supporting scaffolds with consistent morphological integrity, while weaker bases like NaOH/EtOH and ammonia vapors resulted in lower pore sizes and reduced structural stability. Water evaporation studies showed that neutralized samples had slower evaporation rates due to the strong intermolecular interactions formed during the neutralization process, contributing to a stable crosslinked network. FTIR spectra confirmed the formation of polyelectrolyte complexes in the CS-Gel and CS-Gel-Collagen blends, further enhancing structural stability. Swelling tests indicated that neutralized constructs maintained stability in different pH environments, with KOH-treated samples exhibiting the lowest swelling ratios and the highest structural stability. After optimizing the ink composition, 10 wt% Levofloxacin was loaded in the constructs as a model antibiotic and it’s in vitro release rate was quantified. Drug loading was approximately 4 % for both ink compositions GC and CGC. CG Levo released over 80 % of levofloxacin within the first hour, reaching full release in 24 h, indicating inadequate control, while CGK Levo exhibited slower initial release (55 % in 15 min) followed by stabilized release after 4 h, likely due to controlled diffusion from expanded constructs. These findings demonstrate that the developed hydrogel inks and optimized printing parameters can produce scaffolds suitable for tissue engineering applications. Finally, the cell compatibility of the 3D-printed constructs was confirmed with MTT assay on fibroblasts and the antimicrobial activity of the drug-loaded constructs was tested against E. coli and S. aureus, showing an increase of the bacteria free zone from 8 ± 0.4 mm of the control against E. coli up to 16.4 ± 0.37 mm in the presence of the KOH-treated CG Levo printed construct.
生物相容性材料与先进的三维(3D)增材制造技术相结合,在为组织工程和药物输送等生物医学应用开发具有可重现宏观和微观结构特征的微调复杂支架方面具有巨大潜力。本研究开发了基于壳聚糖、胶原蛋白和明胶的生物相容性可打印油墨,并使用气动挤出式打印机进行了三维打印。通过评估打印结构的质量,对各种壳聚糖-明胶(CS-Gel)水凝胶油墨的可打印性进行了评估。这些油墨需要 150 ± 40 兆帕的挤出压力和 G22 和 G25 喷嘴才能达到最佳打印效果。壳聚糖浓度较低的油墨 (
{"title":"Optimization of chitosan-gelatin-based 3D-printed scaffolds for tissue engineering and drug delivery applications","authors":"","doi":"10.1016/j.ijpharm.2024.124776","DOIUrl":"10.1016/j.ijpharm.2024.124776","url":null,"abstract":"<div><div>The combination of biocompatible materials and advanced three-dimensional (3D) additive manufacturing technologies holds great potential in the development of finely tuned complex scaffolds with reproducible macro- and micro-structural characteristics for biomedical applications, such as tissue engineering and drug delivery. In this study, biocompatible printable inks based on chitosan, collagen and gelatin were developed and 3D-printed with a pneumatic-based extrusion printer. The printability of various chitosan–gelatin (CS-Gel) hydrogel inks was assessed by evaluating the quality of the printed constructs. The inks required an extrusion pressure of 150 ± 40 MPa with G22 and G25 nozzles for optimal printing. Inks with low chitosan concentrations (&lt;4% w/v) exhibited poor printability, while inks with 4 % w/v chitosan and 1 % w/v gelatin (CG) demonstrated satisfactory extrusion and printing quality. The addition of collagen (0.1 % w/v) to the optimized ink (CGC) did not compromise printability. Post-printing stabilization using KOH produced self-supporting scaffolds with consistent morphological integrity, while weaker bases like NaOH/EtOH and ammonia vapors resulted in lower pore sizes and reduced structural stability. Water evaporation studies showed that neutralized samples had slower evaporation rates due to the strong intermolecular interactions formed during the neutralization process, contributing to a stable crosslinked network. FTIR spectra confirmed the formation of polyelectrolyte complexes in the CS-Gel and CS-Gel-Collagen blends, further enhancing structural stability. Swelling tests indicated that neutralized constructs maintained stability in different pH environments, with KOH-treated samples exhibiting the lowest swelling ratios and the highest structural stability. After optimizing the ink composition, 10 wt% Levofloxacin was loaded in the constructs as a model antibiotic and it’s in vitro release rate was quantified. Drug loading was approximately 4 % for both ink compositions GC and CGC. CG Levo released over 80 % of levofloxacin within the first hour, reaching full release in 24 h, indicating inadequate control, while CGK Levo exhibited slower initial release (55 % in 15 min) followed by stabilized release after 4 h, likely due to controlled diffusion from expanded constructs. These findings demonstrate that the developed hydrogel inks and optimized printing parameters can produce scaffolds suitable for tissue engineering applications. Finally, the cell compatibility of the 3D-printed constructs was confirmed with MTT assay on fibroblasts and the antimicrobial activity of the drug-loaded constructs was tested against E. coli and S. aureus, showing an increase of the bacteria free zone from 8 ± 0.4 mm of the control against E. coli up to 16.4 ± 0.37 mm in the presence of the KOH-treated CG Levo printed construct.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142346640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anatomically-detailed segmented representative adult and pediatric nasal models for assessing regional drug delivery and bioequivalence with suspension nasal sprays 用于评估悬浮鼻腔喷雾剂的区域给药和生物等效性的解剖学细分代表性成人和儿童鼻腔模型。
IF 5.3 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-27 DOI: 10.1016/j.ijpharm.2024.124743
In vitro nasal models can potentially facilitate development and approval of nasal drug products. This study aims to evaluate the potential for using regional deposition measurements from in vitro nasal models to evaluate nasal spray performance across several products. To accomplish this, the posterior regions of six anatomically realistic nasal airway models of adult and pediatric subjects, representing Low (L), Mean (M) and High (H) posterior drug deposition (PD) for each of the two age groups, were segmented with high anatomical precision into five regions of interest. These models were previously developed with the goal of quantifying the range of intersubject variability of PD following administration of inhaled corticosteroids. The in vitro regional drug deposition values were measured for the reference listed drug (RLD) product for triamcinolone acetonide and two corresponding generic (test) nasal spray products, as well as an RLD product for fluticasone furoate nasal spray. In general, the pediatric models mostly demonstrated higher PD compared to the adult models. The majority (>85 %) of PD was confined to the front and the inferior meatus regions. Subsequent population bioequivalence (PBE) analyses of the regional nasal deposition suggested that the anatomical differences among subjects may impact the nasal spray performance across different nasal products.
体外鼻腔模型有可能促进鼻腔药物产品的开发和审批。本研究旨在评估使用体外鼻腔模型的区域沉积测量值来评估几种产品的鼻腔喷雾性能的潜力。为了实现这一目标,我们对成人和儿童受试者的六个解剖逼真的鼻腔气道模型的后部区域(分别代表两个年龄组的低 (L)、中 (M) 和高 (H) 后部药物沉积 (PD))进行了高解剖精度的分割,分为五个感兴趣的区域。这些模型是之前开发的,目的是量化吸入皮质类固醇后PD的受试者间变异范围。体外区域药物沉积值是针对曲安奈德参考上市药物(RLD)产品和两种相应的普通(测试)鼻腔喷雾剂产品以及糠酸氟替卡松鼻腔喷雾剂的 RLD 产品测量的。一般来说,与成人模型相比,儿童模型的 PD 值大多较高。大部分(大于 85%)的 PD 都局限于前部和下肉眼区域。随后进行的鼻腔区域沉积人群生物等效性(PBE)分析表明,受试者之间的解剖学差异可能会影响不同鼻腔产品的鼻腔喷雾性能。
{"title":"Anatomically-detailed segmented representative adult and pediatric nasal models for assessing regional drug delivery and bioequivalence with suspension nasal sprays","authors":"","doi":"10.1016/j.ijpharm.2024.124743","DOIUrl":"10.1016/j.ijpharm.2024.124743","url":null,"abstract":"<div><div>In vitro nasal models can potentially facilitate development and approval of nasal drug products. This study aims to evaluate the potential for using regional deposition measurements from in vitro nasal models to evaluate nasal spray performance across several products. To accomplish this, the posterior regions of six anatomically realistic nasal airway models of adult and pediatric subjects, representing Low (L), Mean (M) and High (H) posterior drug deposition (PD) for each of the two age groups, were segmented with high anatomical precision into five regions of interest. These models were previously developed with the goal of quantifying the range of intersubject variability of PD following administration of inhaled corticosteroids. The in vitro regional drug deposition values were measured for the reference listed drug (RLD) product for triamcinolone acetonide and two corresponding generic (test) nasal spray products, as well as an RLD product for fluticasone furoate nasal spray. In general, the pediatric models mostly demonstrated higher PD compared to the adult models. The majority (&gt;85 %) of PD was confined to the front and the inferior meatus regions. Subsequent population bioequivalence (PBE) analyses of the regional nasal deposition suggested that the anatomical differences among subjects may impact the nasal spray performance across different nasal products.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142346625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
International Journal of Pharmaceutics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1